TakedaRegister for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
Takeda (TAK) reported revenue of $7.81B in Q2 2026.
Q3 2016-Q2 2026
Q3 2016-Q2 2026
TakedaJapanese pharma. Vaccine lens is Qdenga (dengue), Japanese encephalitis, pandemic influenza, and a Novavax relationship in Japan.
Takeda (TAK) is a Drug Manufacturers - General company. Japanese pharma. Vaccine lens is Qdenga (dengue), Japanese encephalitis, pandemic influenza, and a Novavax relationship in Japan. It was founded in 1781, is headquartered in Tokyo, Japan and employs about 47,455 people.
Track Takeda's quarterly and annual revenue, gross and net margins, and EPS in the interactive charts on this page. Data last updated August 19, 2026.
Sterling groups Takeda in the Vaccines sector, alongside GSK (GSK), Pfizer (PFE), Merck & Co. (MRK), Sanofi (SNY), Moderna (MRNA) and BioNTech (BNTX).
If you are researching Takeda, also look at GSK (GSK), Pfizer (PFE) and Merck & Co. (MRK). You can compare all of them side by side or browse the full Vaccines sector on Sterling.